CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
High ImpactOriginal article

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

ABS-1230Positive
AI Analysis

Summary

Jazz Pharmaceuticals is acquiring Actio Biosciences for $820 million upfront to add ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to its rare epilepsy portfolio.

Importance:8/10
Sentiment:
0.70
acquisitionrare epilepsyprecision medicineclinical-stageportfolio expansion
Related Companies

Read the original article

Published by PR Newswire Pharma on August 10, 2026 11:30 AM

Read Original